Pfizer C. Difficile Vaccine Candidate Misses Main Study Endp

By Colin Kellaher


Pfizer Inc. on Tuesday reported mixed results from a Phase 3 study of PF-06425090, its vaccine candidate for the prevention of C. difficile infection, or CDI.

The New... | March 1, 2022

Related Keywords

New York , United States , Colin Kellaher , Pfizer , Pfizer Inc , Dow Jones , Nc Stock Exchange , News , Information , Press Release , Y , Colin , Kellaher , N , Tuesday , Eported , Ixed , Results , Rom , Hase , , Study , F , Its , Vaccine , Candidate , Or , The , Prevention , Difficile , Dr , He Pfe Us7170811035 ,